Current status and future trends of the global burden of MASLD

[1]  Jiahe Tan,et al.  Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults , 2024, Liver international : official journal of the International Association for the Study of the Liver.

[2]  M. Stepanova,et al.  Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. , 2024, Journal of hepatology.

[3]  T. Cheung,et al.  Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future , 2023, Hepatobiliary surgery and nutrition.

[4]  G. Sebastiani,et al.  Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease , 2023, Nature reviews. Gastroenterology & hepatology.

[5]  Z. Younossi,et al.  The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019 , 2023, Hepatology communications.

[6]  M. Ekstedt,et al.  99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. , 2023, Journal of hepatology.

[7]  M. Carbone,et al.  Exploring the landscape of steatotic liver disease in the general US population , 2023, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Grace Lai-Hung Wong,et al.  Can we use old NAFLD data under the new MASLD definition? , 2023, Journal of hepatology.

[9]  Dan-Qin Sun,et al.  Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis , 2023, eGastroenterology.

[10]  Ankur Sharma,et al.  MAFLD: an optimal framework for understanding liver cancer phenotypes , 2023, Journal of Gastroenterology.

[11]  V. Wong,et al.  A multisociety Delphi consensus statement on new fatty liver disease nomenclature , 2023, Hepatology.

[12]  V. Wong,et al.  Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. , 2023, The lancet. Gastroenterology & hepatology.

[13]  H. Tilg,et al.  An international multidisciplinary consensus statement on MAFLD and the risk of CVD , 2023, Hepatology International.

[14]  Abbas M. Hassan,et al.  The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories , 2023, Hepatology.

[15]  F. Tacke,et al.  Global epidemiology of cirrhosis — aetiology, trends and predictions , 2023, Nature Reviews Gastroenterology & Hepatology.

[16]  V. Wong,et al.  Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes , 2023, Hepatology.

[17]  Ana Sánchez-Bao,et al.  Identifying advanced MAFLD in a cohort of T2DM and clinical features , 2023, Frontiers in Endocrinology.

[18]  Jian Song,et al.  Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. , 2023, Diabetes research and clinical practice.

[19]  M. Zheng,et al.  Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis , 2023, BJS open.

[20]  L. Henry,et al.  The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review , 2023, Hepatology.

[21]  L. N. Valenti,et al.  An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease , 2023, Hepatobiliary surgery and nutrition.

[22]  Y. Imai,et al.  The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD , 2022, Nutrients.

[23]  Yazhuo Liu,et al.  Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019 , 2022, Frontiers in Nutrition.

[24]  K. Sung,et al.  Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention , 2022, Cardiovascular Diabetology.

[25]  Zuojia Liu,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment , 2022, International journal of molecular sciences.

[26]  Tamas S. Gal,et al.  Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies , 2022, Frontiers in Endocrinology.

[27]  A. Lonardo,et al.  Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications , 2022, International journal of molecular sciences.

[28]  V. Wong,et al.  Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores , 2022, Journal of hepatology.

[29]  Yingli Lu,et al.  Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China , 2022, Frontiers in Endocrinology.

[30]  C. Guja,et al.  Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies , 2022, Journal of clinical medicine.

[31]  Xin-Lei Zhang,et al.  Promoting the term MAFLD: China in action. , 2022, The lancet. Gastroenterology & hepatology.

[32]  C. Tsalikidis,et al.  Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing? , 2022, Current oncology.

[33]  M. Zheng,et al.  Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives , 2022, Portal Hypertension & Cirrhosis.

[34]  Y. Kono,et al.  Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. , 2022, Cell metabolism.

[35]  M. Zheng,et al.  Non-alcoholic Fatty Liver Disease: Current Global Burden. , 2022, Seminars in liver disease.

[36]  S. Wild,et al.  NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status , 2022, Hepatology.

[37]  Xulei Tang,et al.  Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center , 2022, Journal of diabetes research.

[38]  K. Lam,et al.  Non‐alcoholic fatty liver disease and type 2 diabetes: An update , 2022, Journal of diabetes investigation.

[39]  M. Zheng,et al.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease , 2022, Nature Reviews Nephrology.

[40]  L. Roberts,et al.  Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[41]  R. Malekzadeh,et al.  The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? , 2021, Journal of hepatology.

[42]  M. Zheng,et al.  Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma , 2021, Chinese medical journal.

[43]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[44]  B. Keymeulen,et al.  The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study. , 2021, Acta gastro-enterologica Belgica.

[45]  Myeong Jun Song,et al.  Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.

[46]  Y. Yılmaz,et al.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver , 2021, Journal of clinical and translational hepatology.

[47]  N. H. Cho,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease , 2021, Gut and liver.

[48]  C. Byrne,et al.  Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[49]  Y. Bao,et al.  Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China , 2021, The Journal of clinical endocrinology and metabolism.

[50]  M. Buti,et al.  A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  Z. Younossi,et al.  The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019. , 2021, Journal of hepatology.

[52]  L. Henry,et al.  Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma , 2021, JHEP reports : innovation in hepatology.

[53]  A. Lonardo,et al.  Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management , 2021, Advances in Therapy.

[54]  T. Kadowaki,et al.  Role of Insulin Resistance in MAFLD , 2021, International journal of molecular sciences.

[55]  H. Tilg,et al.  Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies , 2021, Gut.

[56]  F. Negro,et al.  NAFLD and MAFLD as emerging causes of HCC: A populational study , 2021, JHEP reports : innovation in hepatology.

[57]  M. Zheng,et al.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. , 2021, Hepatobiliary surgery and nutrition.

[58]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[59]  J. Weng,et al.  MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy , 2020, Chinese medical journal.

[60]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis , 2020, Gut.

[61]  H. Kirikoshi,et al.  Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs , 2020, Diagnostics.

[62]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[63]  B. Staels,et al.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease , 2020, Molecular metabolism.

[64]  Z. Younossi,et al.  The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017 , 2020, Hepatology communications.

[65]  Xiaojun Ge,et al.  Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study , 2020, BMJ Open.

[66]  T. Goeser,et al.  NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.

[67]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[68]  B. Hanratty,et al.  Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.

[69]  B. Neuschwander‐Tetri.  Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.

[70]  T. H. Nguyen,et al.  The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.

[71]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[72]  T. Therneau,et al.  The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study. , 2019, Journal of hepatology.

[73]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[74]  D. Prati,et al.  Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[75]  A. Suzuki,et al.  Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps , 2019, Hepatology.

[76]  A. Federico,et al.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome , 2019, International journal of environmental research and public health.

[77]  Andrew A. Li,et al.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease , 2019, Gut and liver.

[78]  N. Sattar,et al.  Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts , 2019, BMC Medicine.

[79]  H. El‐Serag,et al.  Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.

[80]  P. Manousou,et al.  Non-alcoholic fatty liver disease , 2018, Clinical medicine.

[81]  L. Henry,et al.  Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2018, Clinics in liver disease.

[82]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[83]  R. Bataller,et al.  Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA , 2017, BMJ Open.

[84]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[85]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[86]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[87]  E. Bugianesi,et al.  Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers , 2016, International journal of molecular sciences.

[88]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[89]  M. Braddock,et al.  Nonalcoholic Fatty Liver Disease , 2015, Medicine.

[90]  D. S̆timac,et al.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. , 2014, World journal of gastroenterology.

[91]  H. Völzke,et al.  Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2014, PLoS medicine.

[92]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[93]  V. Wong,et al.  Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease , 2011, Gut.

[94]  A. Stadlmayr,et al.  Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia , 2011, Journal of internal medicine.

[95]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[96]  Y. Cho,et al.  Relationship of non‐alcoholic fatty liver disease to colorectal adenomatous polyps , 2010, Journal of gastroenterology and hepatology.

[97]  G. Targher,et al.  2022 KLCA-NCC HCC practice guideline , 2022 .